Email this article Exosomal microRNAs released from tumor cells can play a role as reliable non-invasive biomarkers in the diagnosis and prognosis of breast cancer
Abstract
Breast cancer is one of the leading causes of death in women. Breast cancer develops from the milk-producing cells of the breast tissue. Exosomes from breast cancer cells have been linked to proliferation, metastasis, chemoresistance, and carcinogenesis, according to research. Exosomes are membrane-bound extracellular vesicles that can be secreted from cancer cells and contain a variety of contents such as nucleic acid, protein, lipid, etc. MicroRNAs, a component of exosomes, are small non-coding RNAs that dysregulate in various cancers and can function as oncogenic or suppressive RNA. MiRNAs influence cancer progression by binding to the 3' or 5' UTR (untranslated region) of their target. Because of their important role in cancer tumorigenesis, progression, and metastasis, some novel diagnostic and prognosis tools have been developed. In this study, we list some prominent exosomal microRNA, the key function of some specific exosomal miRNA, and their ability to act as a biomarker or a new therapy that they have been researching since 2020.
Keywords
Full Text:
Full-text PDFReferences
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97.
Pogue AI, Clement C, Hill JM, Lukiw WJ. Evolution of microRNA (miRNA) Structure and Function in Plants and Animals: Relevance to Aging and Disease. J Aging Sci. 2014; 2(2):119.
Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018; 15(10):617-38.
Sempere LF, Keto J, Fabbri M. Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications. Cancers (Basel). 2017; 9(7):71.
Xie JX, Fan X, Drummond CA, Majumder R, Xie Y, Chen T, et al. MicroRNA profiling in kidney disease: Plasma versus plasma-derived exosomes. Gene. 2017; 627:1-8.
Xu J, Han K, Liu D, Lin L, Miao P. Isothermal amplification detection of miRNA based on the catalysis of nucleases and voltammetric characteristics of silver nanoparticles. Molecular BioSystems. 2016; 12(12):3550-5.
Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012; 1826(1):103-11.
Yang SS, Ma S, Dou H, Liu F, Zhang SY, Jiang C, et al. Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment. Exp Cell Res. 2020; 391(2):111983.
Jang JY, Kim YS, Kang KN, Kim KH, Park YJ, Kim CW. Multiple microRNAs as biomarkers for early breast cancer diagnosis. Mol Clin Oncol. 2021; 14(2):31.
Barcellos-Hoff MH, Cucinotta FA. New tricks for an old fox: impact of TGFβ on the DNA damage response and genomic stability. Sci Signal. 2014; 7(341):re5.
De S, Campbell C, Venkitaraman AR, Esposito A. Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage. Cell Rep. 2020; 30(7):2083-93.e5.
Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q, et al. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing. Oncol Rep. 2020; 43(1):240-50.
Hirschfeld M, Rücker G, Weiß D, Berner K, Ritter A, Jäger M, et al. Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection. Mol Diagn Ther. 2020; 24(2):215-32.
Zhang Z, Zhang L, Yu G, Sun Z, Wang T, Tian X, et al. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer Chemother Pharmacol. 2020; 86(6):761-72.
Yao S, Yin Y, Jin G, Li D, Li M, Hu Y, et al. Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance. Cancer Med. 2020; 9(16):5989-98.
Shen S, Song Y, Zhao B, Xu Y, Ren X, Zhou Y, et al. Cancer-derived exosomal miR-7641 promotes breast cancer progression and metastasis. Cell Commun Signal. 2021; 19(1):20.
Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7(3):e30679.
Chen B, Sang Y, Song X, Zhang D, Wang L, Zhao W, et al. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics. 2021; 11(8):3932-47.
Liu D, Li B, Shi X, Zhang J, Chen AM, Xu J, et al. Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers. Aging (Albany NY). 2021; 13(3):4258-73.
Tian F, Shen Y, Chen Z, Li R, Ge Q. No Significant Difference between Plasma miRNAs and Plasma-Derived Exosomal miRNAs from Healthy People. Biomed Res Int. 2017; 2017:1304816.
de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96(10):1504-13.
Ahmad SS, Ahmed K, Venkitaraman AR. Science in Focus: Genomic Instability and its Implications for Clinical Cancer Care. Clin Oncol (R Coll Radiol). 2018; 30(12):751-5.
Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol. 2011; 3(1):1-3.
Xin Y, Wang X, Meng K, Ni C, Lv Z, Guan D. Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer. Biosci Rep. 2020; 40(1):BSR20190303.
Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages. J Cell Mol Med. 2020; 24(17):9560-73.
Wang B, Mao JH, Wang BY, Wang LX, Wen HY, Xu LJ, et al. Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-κB signaling pathway. Cancer Lett. 2020; 489:87-99.
Wang H, Wei H, Wang J, Li L, Chen A, Li Z. MicroRNA-181d-5p-Containing Exosomes Derived from CAFs Promote EMT by Regulating CDX2/HOXA5 in Breast Cancer. Mol Ther Nucleic Acids. 2020; 19:654-67.
Liu Y, Yang Y, Du J, Lin D, Li F. MiR-3613-3p from carcinoma-associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression. IUBMB Life. 2020; 72(8):1705-14.
Wang J, Zhang Q, Wang D, Yang S, Zhou S, Xu H, et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. J Cell Physiol. 2020; 235(7-8):5722-35.
Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu W, et al. Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020; 39(24):4681-94.
Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z, et al. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Oncotarget. 2017; 8(8):13048-58.
Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques. Theranostics. 2017; 7(3):789-804.
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, et al. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing. Clin Cancer Res. 2017; 23(17):5311-9.
He Y, Deng F, Yang S, Wang D, Chen X, Zhong S, et al. Exosomal microRNA: a novel biomarker for breast cancer. Biomark Med. 2018; 12(2):177-88.
Bhagirath D, Yang TL, Bucay N, Sekhon K, Majid S, Shahryari V, et al. microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Res. 2018; 78(7):1833-44.
Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. J Cell Physiol. 2018; 233(9):6370-80.
Inubushi S, Kawaguchi H, Mizumoto S, Kunihisa T, Baba M, Kitayama Y, et al. Oncogenic miRNAs Identified in Tear Exosomes From Metastatic Breast Cancer Patients. Anticancer Res. 2020; 40(6):3091-6.
Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018; 10:59.
DOI: https://doi.org/10.52547/JCBioR.3.2.62
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 © The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.